Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2016 Feb 15;26(4):1124-9. doi: 10.1016/j.bmcl.2016.01.064. Epub 2016 Jan 22.

Discovery of spirocyclic proline tryptophan hydroxylase-1 inhibitors.

Author information

1
Karos Pharmaceuticals, 401 Winchester Ave., 5 Science Park, New Haven, CT 06511, United States. Electronic address: dgoldberg@karospharma.com.
2
Karos Pharmaceuticals, 401 Winchester Ave., 5 Science Park, New Haven, CT 06511, United States.

Abstract

The central role of the biogenic monoamine serotonin (5-hydroxytryptamine, 5-HT) as a neurotransmitter with important cognitive and behavioral functions is well known. However, 5-HT produced in the brain only accounts for approximately 5% of the total amount of 5-HT generated in the body. At the onset of our work, it appeared that substituted phenylalanine derivatives or related aryl amino acids were required to produce potent inhibitors of TPH1, as significant losses of inhibitory activity were noted in the absence of this structural element. We disclose herein the discovery of a new class of TPH1 inhibitors that significantly lower peripherally 5-HT.

KEYWORDS:

5-HT; Peripheral serotonin; Spirocycle; TPH1

PMID:
26821821
DOI:
10.1016/j.bmcl.2016.01.064
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center